Mount Sinai Tisch Cancer Center | Strategic Alliance Partners

Theresa Shao, MD, assistant professor of hematology-oncology, Icahn School of Medicine, Tisch Cancer Institute, Mount Sinai Health System, discusses the prognosis of patients with HER2-positive breast cancer.

Theresa Shao, MD, discusses the neoadjuvant and adjuvant findings with pertuzumab as well as the adjuvant use of neratinib in patients with locally advanced HER2-positive breast cancer.

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the role of bispecific agents in the treatment of patients with myeloma.

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses the role of immunotherapy in the treatment of patients with myeloma.

Samir Parekh, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses a promising potential biomarker for response to selinexor in patients with myeloma.

Ajai Chari, MD, discusses novel treatment approaches for patients with heavily pretreated multiple myeloma.

Paula Klein, MD, discusses the research surrounding extended adjuvant therapy in early-stage hormone receptor-positive breast cancer.

Much needs to be done to improve interoperability of medical data systems. However, standards and new systems are developing at a rapid pace, affording advantages and efficiencies where, previously, enormous impediments stood in the way.

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Hospital, discusses the treatment of patients with penta-refractory multiple myeloma.

Samir Parekh, MD, associate professor of Medicine, Mount Sinai Health System, discusses the mechanism of action of selinexor in multiple myeloma.

Deepu Madduri, MD, discusses the status of transplant for eligible patients and the developments that are being made with CAR T-cell therapy in multiple myeloma.

Samir Parekh, MD, discusses the excitement of selinexor and venetoclax (Venclexta) as possible additions to the myeloma treatment landscape

Ajai Chari, MD, associate professor of Medicine, Hematology and Medical Oncology, at Mount Sinai Hospital, discusses the use of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) for relapsed patients with multiple myeloma.

Sundar Jagannath, MD, provides insight into the biology of multiple myeloma.

Ajai Chari, MD, discusses some of the available and anticipated combinations for use in patients with relapsed/refractory multiple myeloma.

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses carfilzomib (Kyprolis) dosing in the treatment of patients with multiple myeloma.

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the importance of biology in multiple myeloma.

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the importance of the ARROW trial in multiple myeloma.

Low NR2F1 expression in disseminated tumor cells (DTCs) that is found in bone marrow may be indicative of developing metastatic breast cancer, according to results of a study published in Breast Cancer Research.

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the use of checkpoint inhibitors in multiple myeloma.

Aditya V. Shreenivas, MD, MSCR, says a habit of continuous learning is the ideal way to stay informed about the latest data.

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy.

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immunotherapy in bladder cancer.

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immune checkpoint inhibition in patients with bladder cancer.

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses developing drugs for children with cancer.

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses the treatment of pediatric patients with non-Hodgkin lymphoma.

William K. Oh, MD, discusses treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).

Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.